Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

59°
- Saint Marys, OH (45885)
  Today
  
  Sun and clouds mixed. A stray shower or thunderstorm is possible. High around 80F. Winds SSW at 5 to 10 mph..
  
  Tonight
  
  Partly to mostly cloudy skies with scattered thunderstorms during the evening. Storms may contain strong gusty winds. Low 63F. Winds SW at 5 to 10 mph. Chance of rain 60%.
  
  Updated: August 26, 2026 @ 4:26 am
- Full Forecast

Site search

Home
News
- Local News
Sports
Entertainment
Obituaries
Photos
Videos
e-Edition
Classifieds
Best of 2026

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Addex Therapeutics

< Previous 1 2 3 Next >

Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients

November 14, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Regains Nasdaq Listing Compliance

November 08, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Announces Participation in the Bio-Europe 2023 Conference

November 02, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Completes ADS Ratio Change

October 20, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Announces Plan to Implement ADS Ratio Change

October 06, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex mGlu2 NAM Cognition Program Receives €4 Million Grant

September 20, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference

September 06, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024

September 05, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain

September 04, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update

August 10, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023

August 04, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration

August 03, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder

July 24, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Increases Issued Share Capital to Create Treasury Shares

June 15, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Shareholders Approve All Resolutions at Annual General Meeting

June 01, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

May 18, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Reports Q1 2023 Financial Results and Provides Corporate Update

May 11, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study

May 10, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Convenes Annual General Meeting 2023

May 05, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023

May 04, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Completes $5.0 Million Equity Financing

April 05, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson’s Disease

April 04, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Raises $5.0 Million in Equity Financing

April 03, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Reports Full Year 2022 Financial Results and Provides Corporate Update

March 30, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023

March 28, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Announces Upcoming Conferences it will participate for H1 2023

March 16, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Regains Nasdaq Listing Compliance

February 09, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1

February 06, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex Provides Corporate Update and Financial Guidance

January 19, 2023

From Addex Therapeutics

Via GlobeNewswire

Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration

December 08, 2022

From Addex Therapeutics

Via GlobeNewswire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Entertainment
Business
Announcements
Obituaries
Local Events
Multimedia
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

The Evening Leader

theeveningleader.com
102 E. Spring St.
Saint Marys, Ohio 45885
Phone: 419-394-7414
Email: editor@theeveningleader.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Saint Marys, OH (45885)

Today

Tonight

Articles published by Addex Therapeutics

Sections

Services

The Evening Leader